MiNK Therapeutics, Inc. (INKT)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $10.35
- As of
Kresmion compiles this page from INKT's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
MiNK Therapeutics, Inc. (INKT): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-13.
See the full INKT dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for INKT on one page. Preview it with sample data, then open it live with a free account.
Preview the INKT dossierActive events for INKT
- medium13F: new position
CITADEL ADVISORS LLC new position in INKT
- mediumEarnings below estimates
Q2-2025: Missed consensus by 90.1% - EPS $-1.06 vs $-0.5576 estimate
- mediumEarnings above estimates
Q3-2025: Beat consensus by 25.5% - EPS $-0.65 vs $-0.8721 estimate
- mediumEarnings above estimates
Q4-2025: Beat consensus by 33.6% - EPS $-0.555 vs $-0.8364 estimate
- mediumEarnings above estimates
Q1-2026: Beat consensus by 27.4% - EPS $-0.57 vs $-0.7854 estimate
FREE, NO ACCOUNT
Every event on INKT, as it fires
New filings, 13F moves and cross asset events on INKT land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
INKT positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| CITADEL ADVISORS LLC FundCUSIP 603693201 · 2026Q2 | $180K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, INKT
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
Going concern statement
INKT's 10-Q filed Aug 13, 2026 states:
…the Company is required to disclose that substantial doubt exists about its ability to continue as a going concern for a period of one year after the date of filing of this Quarterly Report on Form 10-Q.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on INKT
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in INKT on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on INKT in the last 180 days.
Upstream: SEC EDGAR filings for INKT
Kresmion, "MiNK Therapeutics, Inc. (INKT) institutional holdings and SEC filings", data as of 2026-08-16, https://kresmion.com/research/INKT. Upstream data: SEC EDGAR filings for INKT.
Link to this data (HTML):
<a href="https://kresmion.com/research/INKT">MiNK Therapeutics, Inc. (INKT) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow INKT on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to INKT for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.